Suggestion for a new classification of parenteral cephalosporins;Vorschlag für eine neue einteilung der parenteralen cephalosporine

Chemotherapie Journal

Volumn 18, Issue 4, 2009, Pages 145-146

  Shah, Pramod M ^a   Kresken, Michael ^b   Höffken, Gert ^c,d  

^a Infektiologie   (Germany)

^b BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d Fachkrankenhaus Coswig   (Germany)

Author keywords

Antibiotics; Cephalosporins; Classification

Indexed keywords

CEFACETRILE; CEFALORIDINE; CEFALOTIN; CEFAMANDOLE; CEFAPIRIN; CEFAZEDONE; CEFAZOLIN; CEFEPIME; CEFMENOXIME; CEFODIZIME; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOTIAM; CEFOXITIN; CEFPIROME; CEFTAROLINE; CEFTAZIDIME; CEFTIZOXIME; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; LATAMOXEF;

DRUG CLASSIFICATION; MEDICAL SOCIETY; NOTE;

EID: 69249212355     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Anonymous. Cephalosporine zur parenteralen Applikation. Konsensuskonferenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Chemother J 1994;3:101-115
2. Anonymous. Neuzulassungen/Nouvelles autorisations. Swissmedic J 2008;7:881-889
3. Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and β-lactams. Int J Antimicrob Agents 2002;20:366-74.
4. Fille M, Mango M, Lechner M, et al. Bacteroides fragilis group: trends in resistance. Curr Microbiol 2006;52:153-157
5. Huppertz K, Noll I, Pfister W, et al. ESBL-strains of E. coli and K. pneumoniae in GENARS hospitals. 2005: E-pub ahead of print.
6. Kresken M, Hafner D, Schmitz F-J, et al. Resistenz bei häufig isolierten Enterobacteriaceae gegenüber Breitspektrum-Antibiotika. Chemother J 2006;15:179-190
7. Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008;9:201-209
8. Shah PM, Schaefer V, Ziemen M, et al. Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. J Antimicrob Chemother 1992;29(Suppl A):75-80.
9. Shah PM, Stille W. In-vitro-Aktivität von Cefepim gegenuber Septikämieerregern. Chemother J 1995;4:138-140
10. Shah PM, Wiedemann B, Grimm H, et al. In vitro activity of various antibiotics against pathogens isolated from blood cultures - Results of a multicentre study in Germany. 2nd ECC/BICON-7, Hamburg, 1998.
11. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-1655
12. Vogel F, Bodmann K-F. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J 2004;13:46-105.
13. Vogel F, Naber KG, Wacha H, et al. Parenterale Antibiotika bei Erwachsenen. Chemother J 1999;8:3-49.
14. Witte W, Mielke M. Beta-Lactamasen mit breitem Wirkungsspektrum. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitschutz 2003;46:881-890